Iantrek announces 1-year clinical results of its bio-interventional technology for uveoscleral outflow enhancement in open-angle glaucoma patients

(Image Credit: AdobeStock)

Iantrek Inc announced 1-year results from the company’s prospective multi-center real-world evidence study of open-angle glaucoma patients who underwent uveoscleral outflow enhancement surgery using the company’s interventional cyclodialysis system, combined with adjunct allogeneic bio-tissue reinforcement.

The company announced it will present topline results at the 2024 American Academy of Ophthalmology Annual Meeting, being held October 18 to 21 in Chicago, Illinois. The study data also has been submitted for peer-reviewed publication.

According to the company, the initial study cohort with 12-month data available consists of 117 eyes with open-angle glaucoma (OAG) for which uveoscleral outflow enhancement was performed alongside cataract surgery. The bio-interventional procedure was well tolerated, with a low incidence of minor, transient adverse events.¹

At 12 months, the mean medicated intraocular pressure (IOP) decreased by 27.1% from baseline, with hypertensive eyes (baseline medicated IOP > 21 mmHg) showing a 39.7% reduction. Additionally, 81.9% of all eyes achieved a medicated IOP ≤18 mmHg without an increase in ocular hypotensive medications. Adverse events were transient and non-serious.

The current results follow a separate publication of the surgical outcomes of Iantrek’s uveoscleral bio-interventional technology in the August edition of the Journal of Clinical Medicine.²

The company also noted its inventive approach uses next-generation interventional instrumentation to create a cyclodialysis to enhance internal aqueous uveoscleral outflow, followed by delivery of 100% biologic, allogeneic tissue to reinforce and maintain the cyclodialysis cleft.

Currently, there are no other uveoscleral outflow technologies available on the US market, and interventional access to the uveoscleral pathway is considered the most significant unmet need in the surgical treatment of glaucoma. The uveoscleral outflow pathway has the highest therapeutic index in glaucoma pharmacotherapy with significant potential in surgical applications.

Arsham Sheybani, MD, associate professor of Ophthalmology at Washington University and first author of the AAO abstract, lauded the data.

“Based on this data, having a sustained effect in the uveoscleral space with a novel biomaterial may expand our treatment options for glaucoma,” Sheybani said in a statement.

Ike Ahmed, MD, professor and director of the Moran Eye Center’s Alan S. Crandall Center for Glaucoma Innovation at the University of Utah, noted there are a number of solutions for trabecular outflow surgery ophthalmologists can use today.

“Iantrek’s technology uniquely intervenes in the uveoscleral outflow physiology which has been a long-standing unmet need,” he said. “A safe and effective interventional approach to the uveoscleral outflow is well overdue.”

References:

1. Iantrek I. Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients. GlobeNewswire News Room. Published September 17, 2024. Accessed September 17, 2024. https://www.globenewswire.com/news-release/2024/09/17/2947355/0/en/Iantrek-Announces-1-Year-Clinical-Results-of-Its-Bio-Interventional-Technology-for-Uveoscleral-Outflow-Enhancement-in-Open-Angle-Glaucoma-Patients.html

2. Chaya CJ, Herndon LW, Lince J, Radcliffe N, Sadri E, Yadgarov A, Ianchulev T. Surgical Outcomes, Ocular Safety and Tolerability of Bio-Interventional Cyclodialysis with Allograft Scleral Reinforcement: Clinical Experience of More than 240 Cases. J Clin Med. 2024 Aug 6;13(16):4593. doi: 10.3390/jcm13164593. PMID: 39200737; PMCID: PMC11354769.